| Autor: |
Bruno Mihout, Hartmut Göbel, Werner Becher, Jesper Tørring, Paul Winter, Jur Niewold, Adam Crisp, Tove Hange, Diane Boswell |
| Rok vydání: |
2000 |
| Předmět: |
|
| Zdroj: |
Clinical Therapeutics. 22:981-989 |
| ISSN: |
0149-2918 |
| Popis: |
Objective This randomized, double-blind, crossover study was undertaken to compare the incidence of headache recurrence after treatment with naratriptan or sumatriptan in migraine patients with a history of frequent headache recurrence (recurrence in ≥50% of successfully treated attacks). Background Although the selective 5-hydroxytryptamine 1 (5-HT,) agonist sumatriptan is effective and well tolerated for acute treatment of migraine in most patients, headache recurrence within 24 hours of initial successful treatment with sumatriptan and other medications has been reported in ~35% of patients. The novel 5-HT 1 agonist naratriptan possesses pharmacologic and pharmacokinetic characteristics that may address the issue of headache recurrence. Methods Men and women aged 18 to 65 years with a a ≥1-year history of migraine with or without aura were randomly assigned to treat 1 moderate or severe migraine attack in a nonclinical setting with one 2.5-mg naratriptan tablet and 1 attack with one 100-mg sumatriptan tablet. A pain-free interval of ≥24 hours was required between attacks. At 4 hours, patients not using rescue medication and experiencing headache recurrence could take a second, identical dose of study medication to treat recurrence. No more than 2 tablets of study medication were permitted in any 24-hour period. Results A total of 253 patients treated ≥1 migrane attack and were included in the safety analysis; the 225 patients who treated both attacks were included in the efficacy analysis. Of the 164 naratriptan-treated and 181 sumatriptan-treated patients experiencing headache relief after ≥1 attack, headache recurrence 4 to 24 hours after treatment was reported by 74 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect